



CrossMark

“The therapy of idiopathic pulmonary fibrosis: what is next?” Vivien Somogyi, Nazia Chaudhuri, Sebastiano Emanuele Torrisi, *et al.* *Eur Respir Rev* 2019; 28: 190021.

Unfortunately, in this article in the September 2019 issue of the *European Respiratory Review*, the mechanism of action for PBI-4050 in table 2 was presented incorrectly as anti-CTGF antibody. The correct mechanism of action should be GPR84 antagonist/GPR40 agonist. The article has been corrected and republished online.

Copyright ©ERS 2019.
This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.